Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

LGC Acquires Seracare Life Sciences, Strengthening its Position in Clinical Quality Control Tools

publication date: Dec 7, 2018
 | 
author/source: LGC

LGCLGC has announced the acquisition of SeraCare Life Sciences, Inc., a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories. 

SeraCare provides quality control materials for infectious disease testing through their ACCURUN® reagents as well as in the fast growing clinical next-generation sequencing (NGS) market which it addresses through its Seraseq® brand of products for oncology, NIPT and inherited disease testing.

The acquisition of SeraCare strengthens LGC’s position across the spectrum of clinical quality control tools market and builds upon its existing calibration verification materials and proficiency testing offerings including those of LGC Maine Standards, acquired in 2015. Additionally, the Seraseq clinical genomics tools are complementary to LGC’s component offering to the NGS market which includes oligonucleotides, molecular biology enzymes and magnetic beads.

SeraCare’s global customer base includes in-vitro diagnostics assay developers and manufacturers, clinical laboratories, pharmaceutical companies and proficiency providers.

Euan O’Sullivan, Managing Director, LGC’s Standards division, said: “We are excited to welcome SeraCare to our Standards division. The team will be a natural fit and addition to our existing calibration verification business, providing an expanded portfolio of quality control solutions to customers. This significant acquisition will also strengthen our presence in the fast-growing molecular diagnostics and NGS reference materials market, complementing our genomics offering. We look forward to welcoming our new colleagues into our organisation.”

“SeraCare has earned the trust and confidence from its customers for over 30 years by enabling the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result,” said Charlie Mamrak, CEO of SeraCare Life Sciences.  “We are delighted to be joining LGC as an integral part of their growing clinical diagnostics business. Even more so, we are excited to join an organization that shares our purpose and mission in the support our diagnostics customers by providing best-in-class products and services.”

Founded in 1984 as Boston Biomedica Inc. (BBI), SeraCare currently employs 170 people and is certified to ISO 13485:2016. The company will continue to operate from its two sites, in Milford, MA and Gaithersburg, MD under LGC’s ownership.

 

more from LGC




 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners